Transplantation (HCV)

IFN/Ribavirin Combination May Prevent Graft Disease

Published in Hepatitis Weekly, December 16th, 1996

A treatment approach combining interferon with ribavirin may help prevent progression of hepatitis C virus-related graft disease after liver transplantation, according to a report from France.

Researcher Thierry Bizollon and colleagues found the combination treatment to be well-tolerated in their group of transplant patients ("New Approaches to Treatment of Recurrent HCV Following Liver Transplantation Using Ribavirin," Transplantation Proceedings, October 1996;XXVIII(5):2842-2843).

Cirrhosis caused by chronic hepatitis C virus (HCV) is one of the leading indications for orthotopic liver transplantation in the United States and western Europe, and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1996-12-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry